Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Extensive Small Cell Lung Cancer × Etoposide × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 34 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Lymphoma, Large B-Cell, Diffuse 23 Leukemia, Myeloid, Acute 19 Burkitt Lymphoma 17 Lung Neoplasms 16 Lymphoma, Non-Hodgkin 14 Lymphoma 14 Hodgkin Disease 14 Leukemia 11 Recurrence 10 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9 Lymphoma, Mantle-Cell 9 Lymphoma, B-Cell 9 Carcinoma, Non-Small-Cell Lung 9 Medulloblastoma 8 Multiple Myeloma 7 Lymphoma, Follicular 7 Brain Neoplasms 7 Neuroblastoma 6 Neoplasms, Germ Cell and Embryonal 6 Ependymoma 6 Sarcoma, Ewing 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Neoplasms 5 Lymphoma, B-Cell, Marginal Zone 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Myelodysplastic Syndromes 4 Lymphoma, T-Cell, Peripheral 4 Immunoblastic Lymphadenopathy 4

Interventions

Etoposide 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07083375 2025-07-24

QL1706

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting

Extensive Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡